angiotensin II antagonist

One of a range of drugs that act directly on angiotensin at its receptor sites so as to block its action. These drugs include CANDESARTAN, IRBESARTAN, LOSARTAN, VALSARTAN, telmisartan (Micardis), Olmesartan (Olmetec) and eprosartan (Teveten).

Mentioned in ?

References in periodicals archive ?

Racine-Poon, An Interaction Study with Cimetidine and the New Angiotensin II Antagonist Valsartan, Eur.

Liquid Chromatography Method Development and Optimization for Valsartan: Pharmacokinetics of Oral Hydrogels in Rabbits

Antihypertensive medicines dispensed for free during SNP were: (i) beta-blocking agents: atenolol 25 mg and propranolol hydrochloride 40 mg; (ii) diuretics: hydrochlorothiazide 25 mg; and (iii) agents acting on the renin-angiotensin system inhibitors (Class C09 on European Pharmaceutical Marketing Research Association (EphMRA) Anatomical Classification) including (a) the angiotensin-converting-enzyme (ACE) inhibitors captopril 25 mg and enalapril maleate 10 mg; and (b) the angiotensin II antagonist or angiotensin receptor blocker (ARB) losartan potassium 50 mg (10).

Fischer, "Effects of angiotensin II and angiotensin II antagonist saralasin on cell growth and renin in 3T3 and SV3T3 cells," Journal of Cellular Physiology, vol.

Alterations in Gene Expression of Components of the Renin-Angiotensin System and Its Related Enzymes in Lung Cancer

Arakawa, "Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation," Circulation, vol.

Relationship between Angiotensin Converting Enzyme, Apelin, and New-Onset Atrial Fibrillation after Off-Pump Coronary Artery Bypass Grafting

Post hoc analyses from the Reduction of Endpoints in NIDDM (non-insulin-dependent diabetes mellitus) with the Angiotensin II Antagonist Losartan Study (RENAAL) trial in patients with diabetes illustrated that each 50% reduction in albuminuria induced by treatment with an angiotensin-receptor blocker (ARB) during the first months of therapy was associated with 45% and 18% risk reduction for renal and CV events, respectively, during the ensuing 3.4 years of follow-up (Table 1 and Fig.

Drug-induced changes in risk/biomarkers and their relationship with renal and cardiovascular long-term outcome in patients with diabetes

The ANTIPAF (Angiotensin II Antagonist in Paroxysmal Atrial Fibrillation) trial involved a total of 425 patients at 37 participating German centers.

Trial nixes ARBs for atrial fibrillation: stand-alone angiotensin inhibitor treatment did not curb fibrillations over a 1-year period

(5) The Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study in which patients with T2DM and nephropathy were randomised to losartan or placebo in addition to conventional treatment reported a 16% risk reduction (p=0.02) of primary outcome in patients treated with losartan compared with the placebo group.

Renoprotection in diabetes mellitus: end-stage renal disease is a common and important complication of diabetes

The Heart Failure Endpoint Evaluation of Angiotensin II Antagonist Losartan (HEAAL) trial enrolled patients with symptomatic, New York Heart Association class II-IV heart failure who had a left ventricular ejection fraction of 40% or less.

High losartan dose reduced HF deaths

The principle active valsartan is a nonpeptide, orally active and specific angiotensin II antagonist acting on the [AT.sub.1] receptor subtype.

A comparative, cross-over, double blind, randomized study for bioequivalence assessment between two formulations of valsartan capsules vs. tablets/Estudio comparativo, cruzado, doble ciego, al azar para determinar la bioequivalencia entre dos formulaciones de valsartan en tabletas y capsulas

Findings from the Irbesartan Diabetic Nephropathy Trial (IDNT) and the Reduction of Endpoints in NIDDM with Angiotensin II Antagonist Losartan (RENAAL) indicate that ARBs are more effective than other agents in slowing the progression of kidney disease in patients with macroalbuminuria due to type 2 diabetes.

ACE inhibitors and ARBs: antihypertensive medications in CKD

Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan.

Selective aldosterone blockade reduces mortality after MI. (Patient Oriented Evidence That Matters: practice recommendations from key studies)

COZAAR is the world's most widely prescribed medication in the angiotensin II antagonist class and it continues its strong growth, as physicians increasingly recognize the excellent tolerability and efficacy of these two products.